Pilot Projects Program

太平洋创新、知识和机会中心（Center for Pacific Innovations，Knowledge，and Opportunities，PIKO）的主要目标是： 为临床和转化研究（CTR）开发强大的基础设施，旨在减轻健康 土著太平洋人（IPP），定义为夏威夷土著人，其他太平洋岛民， 菲律宾人，以及其他服务不足的人群（例如，移民，无家可归者，性和性别 少数民族）。为实现这一目标，将设计一个试点项目方案， 竞争基础上，初级研究者（JI）和既定研究者（EI）谁是寻求 他们的研究计划发生了重大变化。他们将来自夏威夷大学的教师， 夏威夷太平洋大学和檀香山的查米纳德大学。资金将优先用于创新， 高质量，有影响力的T1-T5 CTR试点项目，重点是T3-T5，加速翻译 临床和生物医学研究，以更好的病人护理和改善公共卫生的IPP和其他 服务不足的人群。为试点项目提供支助预计将导致加强研究 提高生产率和竞争力，使联合执行/环境影响倡议的校外供资主流化。此外，考虑到严重的 对NIH资助的科学劳动力老龄化的担忧，以及IPP首席研究员的缺乏， 我们会积极鼓励国际合作伙伴联合执行/环境影响评估的申请。因此，PPP核心目标将通过以下方式实现： 以下具体目标： 具体目标1：通过制定资格标准，征求、审查和资助有价值的试点项目， 管理招标程序和申请提交过程;以及制定审查标准， 管理评审、资金决策和奖励审批流程。 具体目标2：通过监测和评估，对试点项目进行授标后监督和评价。 评估获奖者的表现、进度、生产力和投资回报;并确保 获奖者遵守执行CTR的联邦政策、规则和指导方针。 到五年结束时，PIKO公私伙伴关系核心将资助35至45个联合执行/教育倡议， 和科学严谨的CTR试点项目，重点是改善IPP的健康和其他医疗 服务不足和弱势群体。这些试点项目的初步数据将用于确保 联邦和国家拨款资助。大多数得到资助的联合执行/环境倡议将来自独立伙伴关系背景，从而增加 成功竞争NIH或其他校外资金的IPP研究人员的数量。

The overarching goal of the Center for Pacific Innovations, Knowledge, and Opportunities (PIKO) is to develop a robust infrastructure for clinical and translational research (CTR), intending to mitigate health disparities in Indigenous Pacific People (IPP), defined as Native Hawaiians, Other Pacific Islanders, and Filipinos, as well as in other underserved populations (e.g., immigrants, homeless, and sexual and gender minorities). To achieve this goal, a Pilot Project Program (PPP) will be designed to provide funding, on a competitive basis, to Junior Investigators (JI) and Established Investigators (EI) who are seeking to make significant changes to their research program. They will come from the faculty of the University of Hawaii, Hawaii Pacific University, and Chaminade University of Honolulu. Funding will be prioritized toward innovative, high quality, and impactful T1–T5 CTR pilot projects, with an emphasis on T3-T5, that accelerate the translation of clinical and biomedical research into better patient care and improved public health for IPP and other underserved populations. The provision of support for pilot projects is expected to result in heightened research productivity and increased competitiveness for mainstream extramural funding for JI/EI. Also, given the serious concerns about the aging of the NIH-funded scientific workforce, and the dearth of IPP principal investigators, we will actively encourage applications from IPP JI/EI. Thus, the PPP Core objective will be achieved through the following Specific Aims: Specific Aim 1: Solicit, review, and fund meritorious pilot projects by developing eligibility criteria, and managing solicitation procedures and application submission processes; and by establishing review criteria and managing review, funding-decision, and award-approval processes. Specific Aim 2: Provide post-award oversight and evaluation of pilot projects by monitoring and evaluating the performance, progress, productivity, and return on investment of the awardees; and by assuring awardees comply with federal policies, rules, and guidelines for conducting CTR. By the end of five years, the PIKO PPP Core will have funded 35 to 45 JI/EI to conduct culturally responsive and scientifically rigorous CTR pilot projects focused on improving the health of IPP and other medically underserved and vulnerable populations. Preliminary data from these pilot projects will be used to secure federal and national grant funding. Most of the funded JI/EI will be from IPP backgrounds, thereby increasing the number of IPP investigators successfully competing for NIH or other extramural funding.